Neutrophil-activating therapy for the treatment of cancer
Ian L. Linde(Stanford University), Edgar G. Engleman(Stanford Medicine)
Cited by 196
Related Papers
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
|Annual Review of Pathology Mechanisms of Disease|2020|2.2k
Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants
|American Journal of Transplantation|2012|190
B-1a Lymphocytes Attenuate Insulin Resistance
|Diabetes|2014|109
Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer
|Journal of Clinical Investigation|2024|41
Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity
|JCI Insight|2016|27